SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years
NCT07845994 on ClinicalTrials.gov · last registry update 2026-09-29
A small phase 3 — 50 participants, against a typical 424. Due to report February 2031. Primary outcome, as filed: Change in BMI SD score (according to french references) at 40 weeks. Sponsors move these dates routinely; any movement since this site started watching is listed below. The registry entry has been edited 1 time since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- University Hospital, Angers
- Sponsor type
- Other Gov
- Enrollment
- 50
- Started
- 2026-11
- Primary completion
- 2031-02 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-29 | First seen in registry | Registered as NOT_YET_RECRUITING, P3 |
Primary outcome
Change in BMI SD score (according to french references) at 40 weeks
Conditions studied
Craniopharyngioma, Child
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.